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Abstract Basic fibroblast growth factor (FGF-2) is an im-
portant modulator of cell growth and differentiation under both
physiological and pathological conditions. Until recently, most
investigations into the FGF-2 signalling pathway were concerned
with its interaction with specific membrane receptors. Never-
theless, while a 18 kDa protein of FGF-2 is cytosolic, there are
also co-translated high molecular weight (HMW) isoforms that
are predominantly located in the cell nucleus. An increasing
amount of data strongly argue in favour of distinct biological
functions depending on the subcellular location of the FGF-2
species. This review describes the evidence concerning the strictly
intracellular mode of action of the HMW isoforms of FGF-2.
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1. Introduction
Basic ¢broblast growth factor (bFGF or FGF-2) was ¢rst
characterised in 1974 as having proliferative activity for ¢bro-
blastic cells, and belongs to the 18 member family of ¢bro-
blast growth factors. FGF-2 is a multifunctional cytokine,
involved in the proliferation and di¡erentiation of a broad
spectrum of mesodermal and neuro-ectodermal cell types.
The ¢ndings describing the pleiotropic functions exerted by
this single molecule in various physiological systems and dur-
ing the developmental process (reviewed in [1]) strongly sug-
gest that its biological activities arise from multiple signal
transduction pathways.
The biological activity of FGF-2 is highly modulated, re-
sulting from regulatory events occurring at each step of its
synthesis. Di¡erent molecular isoforms of FGF-2 have been
characterised, representing alternative translation products
from a single mRNA. While the 18 kDa protein is cytosolic
and e⁄ciently secreted, the high molecular weight isoforms of
FGF-2 (HMW FGF-2) contain nuclear localisation sequence
(NLS)-like signals responsible for their nuclear targetting.
Most studies to date concern the 18 kDa low molecular
weight (LMW) form, acting via its speci¢c transmembrane
receptor (¢broblast growth factor receptor: FGFR) and acti-
vating the subsequent intracellular second messenger cascades.
Until recently, little was known about the FGFR-independent
activities of the HMW isoforms. The purpose of this review is
to give a synopsis of the last 10 years’ research on the bio-
logical signi¢cance and mode of action of the intracellular
forms of FGF-2.
2. FGF-2: from gene to proteins
FGF-2 is encoded by a single-copy gene which includes two
introns and large 5P and 3P untranslated regions (UTR), sug-
gesting important regulation of its expression. The functional
characterisation of the fgf-2 gene promoter identi¢ed multiple
regulatory elements [2,3]. A bidirectional transcription of the
gene gives rise to multiple polyadenylated mRNAs from a
single transcription start site, as well as a 1.5 kb antisense
transcript (gfg) which is complementary to the 3P untranslated
region of the FGF-2 mRNA. This antisense RNA has been
implicated in the transcriptional and post-transcriptional reg-
ulation of FGF-2 expression [4], and contains a long open
reading frame encoding a functional nuclear protein with anti-
mutator nucleotide hydrolase enzymatic activity [5].
In addition, higher molecular weight isoforms of FGF-2
have been described in the brain [6], or in ras-transformed
cells [7]. In 1989, sequencing of the gene showed that an
alternative initiation of translation at CUG codons, located
5P to the AUG codon, accounts for the 24, 22.5 and 22 kDa
proteins in humans, whereas the AUG codon is used to gen-
erate a 18 kDa species (Fig. 1) [8,9]. Recently, Arnaud et al.
[10] described a new 34 kDa isoform of FGF-2, resulting from
the use of a fourth CUG codon on the gene. Hence, the
HMW isoforms are colinear amino-terminal extensions of
the 18 kDa-FGF-2 protein.
3. FGF-2 subcellular localisation and the known subsequent
signalling pathways
It is very likely that a di¡erential subcellular location of the
HMW and 18 kDa FGF-2 (Fig. 1) mediates distinct e¡ects on
cell phenotype. Despite the fact that the protein lacks a con-
ventional secretory signal peptide, 18 kDa FGF-2 is found in
vivo in biological £uids, in plasma and the extracellular ma-
trix. A mechanism for FGF-2 exocytosis via an endoplasmic
reticulum (ER)^Golgi-independent pathway has been de-
scribed [11], involving the catalytic K subunit of Na,K-
ATPase. Once on the cell surface (Fig. 2), FGF-2 can bind to
the low and high a⁄nity receptors: heparan sulphate proteo-
glycans (HSPG) and FGFR, respectively (for reviews, see
[12,13]). The consensual binding model suggests that the for-
mation of a speci¢c side by side heparin-induced FGF-2 dimer
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 1 1 8 9 - 3
*Fax: (44)-181-913 8593.
E-mail: idelrie@nimr.mrc.ac.uk
FEBS 23334 10-2-00
FEBS 23334FEBS Letters 468 (2000) 6^10
is required for dimerisation and activation of the FGF recep-
tor tyrosine kinase, and consequently for the subsequent ini-
tiation of biological responses [14].
In the early 1990s, immuno£uorescence studies with anti-
bodies against FGF-2 showed intense nuclear staining in var-
ious endothelial FGF-2-producing cells and FGF-2-trans-
fected BHK-21 cells [15], as well as in astrocytes and
oligodendrocytes. Di¡erent mechanisms can explain these ob-
servations: the internalisation of the extracellular 18 kDa
FGF-2 proteins, and/or the preferential nuclear location of
the HMW isoforms of the growth factor.
Bouche et al. [16] showed that exogenously added FGF-2
can indeed translocate to and accumulate in the nucleolus of
adult bovine aortic endothelial (ABAE) cells during G0/G1
transition. In coronary venular endothelial cells, up to 50%
of total internalised FGF-2 is also rapidly targeted to the
nucleus [17], suggesting that some biological activities of the
growth factor may be mediated by nuclear FGF-2, subsequent
to its binding to the cell surface receptors. The nucleolar local-
isation of 18 kDa FGF-2 is indeed correlated with the stim-
ulation of ribosomal gene transcription, whose activation is
mediated via the direct interaction of nuclear FGF-2 with the
regulatory subunit of the protein kinase CKII [18]. Stacho-
wiak and colleagues studied the roles and subcellular location
of FGF-2 and its high a⁄nity receptor FGFR-1 in the nerv-
ous system (reviewed in [19]). They showed that following the
transition of cells to a subcon£uent proliferating state, FGFR-
1 translocates in parallel with FGF-2 to the nucleus, where
they both accumulate and act to stimulate transition from the
G0/G1 to the S phase of the cell cycle [20].
Apart from the internalisation process of extracellular 18
kDa FGF-2, the HMW isoforms also account for the nuclear
location of the growth factor. In transfected NIH-3T3 ¢bro-
blasts, SK-Hep-1 or COS cells, the 18 kDa FGF-2 protein is
cytosolic or exported at the cell surface, whereas the HMW
species are preferentially nuclear [21,22]. Using COS cells
transfected with cDNA encoding fusion protein of FGF-2
and chloramphenicol acetyltransferase (CAT), Bugler et al.
[23] demonstrated that the nuclear targeting of HMW FGF-
2 is governed by a 37 amino acid sequence between the second
CUG and the AUG start codons (Fig. 1). Similar results were
Fig. 1. Human FGF-2, from messenger RNA to proteins. Upper panel: the 6774 nucleotide FGF-2 single mRNA contains the 288 bp open
reading frame region (open box) and the 5P and large 3P untranslated regions (black lines). Nucleotide positions relative to the transcription
start site (1) are indicated in brackets. Middle panel: 5P end of the FGF-2 mRNA with the AUG and the non-canonical CUG start codons ac-
counting for the various FGF-2 isoforms. The NLS-like signals are shown (black boxes). The ¢rst one is a PRRRPRR motif similar to the ar-
ginine-rich NLS of the human immunode¢ciency virus type 1 (HIV-1) Rev protein. The second one, located between the CUG3 and the AUG,
is contained with a 37 amino acid sequence which encompasses three GRGR(X)5R motifs. Lower panel: the HMW isoforms initiated from the
CUG codons and the AUG-initiated protein, showing their respective molecular mass and localisation.
Fig. 2. FGF-2 signalling pathways. When secreted at the cell sur-
face, the 18 kDa FGF-2 (white triangle) can bind to the heparan
sulfate proteoglycan (HSPG) receptors and the high a⁄nity receptor
FGFR to act in an autocrine/paracrine manner. Two pathways are
distinguishable, both of which are responsible for subsequent specif-
ic genes activation: the tyrosine kinase FGFR signal transduction
pathway (1), or internalisation leading to the colocalisation of both
ligand and active receptor in the cell nucleus (2). The nucleus-tar-
geted HMW isoforms of FGF-2 (black triangle) have an intracrine
mode of action, probably interacting with intracellular partners in
the cytoplasm and/or the nucleus, and also regulating the expression
of speci¢c target genes (3).
FEBS 23334 10-2-00
I. Delrieu/FEBS Letters 468 (2000) 6^10 7
obtained when using proteins containing the amino-terminal
extension of HMW FGF-2 fused to L-galactosidase [24]. Ar-
ginine methylation has been shown to be probably relevant to
the intracellular distribution of these isoforms [25]. Moreover,
the newly discovered 34 kDa protein of FGF-2 contains an
additional functional arginine-rich NLS sequence, similar to
the NLS of human immunode¢ciency virus type 1 Rev protein
[10].
4. FGF-2 isoforms display di¡erential patterns of expression
The di¡erent isoforms of FGF-2 display speci¢c patterns of
expression depending on tissue, species, developmental stage
or cellular stress conditions. When comparing normal and H-
ras-transformed Rat-1 ¢broblasts [7], a preferential increase in
the HMW FGF-2 protein level is observed as a consequence
of cell transformation. In the rat central nervous system, the
HMW 24 kDa isoform is developmentally regulated [26], ap-
pearing only after birth and reaching maximum levels in the
adult. In contrast, in the development of the rat heart, HMW
FGF-2 progressively disappears during the progression from
immature to di¡erentiated cardiac phenotype, and this occurs
predominantly for the synthesis of the 18 kDa isoform [27].
Moreover, expression of the HMW but not of the 18 kDa
isoform is selectively increased by cytokines such as interleu-
kin 1L (IL-1L) or tumour necrosis factor K in rat hippocampal
astrocyte cultures [28]. Speci¢c translation of the CUG-initi-
ated FGF-2 protein is activated in transformed cells, as well
as in stressed primary skin ¢broblasts in response to heat
shock and oxidative stress [29]. This di¡erential regulation
of FGF-2 isoform expression occurs via both a cap-dependent
and cap-independent initiation of translation, involving at
least one internal ribosomal entry site (IRES) in the FGF-2
mRNA [30]. Alternative translation mechanisms involving
trans-acting factors speci¢c to transformed and stressed cells
are responsible for the di¡erential expression of the HMW
proteins [29].
5. Speci¢c e¡ects of HMW FGF-2 on cell phenotype
On the basis of the latest studies, it has been suggested that
18 kDa and HMW proteins may serve distinct physiological
functions. Several strategies have been used to address this
possibility, involving the use of antisense RNA molecules
for FGF-2 or selective expression of the di¡erent isoforms
(Table 1).
Couderc et al. [31] observed that the constitutive overex-
pression of recombinant HMW FGF-2 leads to ABAE cell
immortalisation, whereas cells transfected with the 18 kDa
coding vector form colonies in soft agar. In addition, the
tumorigenic potential is reached when all isoforms are consti-
tutively expressed. In NIH-3T3 ¢broblasts, contrary to the
e¡ect of 18 kDa FGF-2, the HMW proteins do not modify
cell migration or FGF receptor number, but allow prolifera-
tion in low serum and cell growth to a high saturation density
[32]. Moreover, when these same cells are cotransfected with a
cDNA encoding FGF receptor lacking the COOH-terminal
domain (dominant negative FGFR-2), only the phenotypes
allocated to the 18 kDa FGF-2 can be reversed, strongly
suggesting a dissociated intracrine activity of the HMW iso-
forms versus the extracellular mode of action of FGF-2. Es-
tival and colleagues performed studies in the rat pancreatic
acinar cancer cell line AR4-2J, which expresses FGF-2 recep-
tors but not FGF-2 proteins. Only the cells transfected with
Table 1
Speci¢c e¡ects of the various FGF-2 isoforms on cell phenotype
Cell type Source of FGF-2 synthesis FGF-2 isoform
(kDa)
Cell phenotype E¡ects of inhibitors References
ABAE selective expression (a) 21/22.5 immortalisation [31]
18 transformation
HMW+LMW tumorigenic potential
NIH-3T3 selective overexpression (b,c) 21/22.5/24 growth in low serum medium
to a high saturation density
FGFR-23 [32,46]
18 increased cell migration FGFR-23
AR4-2J selective expression (a) 22.5 proliferation in serum-free
medium
[33]
HMW+LMW
Schwann cell
precursors
TPA-induced expression HMW+LMW trans-di¡erentiation into
melanocytes
antisense FGF-2 RNA, [35]
Ab K-FGF-2, InsP6
SK-Hep1 endogenous expression HMW+LMW transformation/tumorigenicity antisense FGF-2 RNA [36]
rat cardiac
myocytes
selective overexpression (c) 21.5/22 (rat) cell binucleation Ab K-FGF-2 [37]
18 proliferation Ab K-FGF-2
HeLa selective expression (a) 24 radioresistance (Q-rays) [38]
Glioma cells endogenous expression HMW+LMW proliferation antisense FGF-2 RNA [19,39]
selective overexpression (c) HMW+LMW increased proliferation InsP6
PC-12 selective overexpression (c) 21/23 stabilisation of the endocrine
phenotype
[40]
18 di¡erentiation towards the
neuronal phenotype
Expression vectors: (a) retroviral; (b) adenoviral; (c) plasmidic. FGFR-23 : dominant negative FGF receptor-2; InsP6: antagonist of FGFR
binding; K-FGF-2: neutralising antibody. : blocking action; : no blocking action.
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the HMW FGF-2 were able to grow in serum-free medium
and revealed a strong increase in both high and low a⁄nity
receptors, hence enhancing cell responses to exogenous FGF-2
[33,34]. The use of neutralising anti-FGF-2 antibodies and
suramin did not reverse these e¡ects.
In the central nervous system, FGF-2 or 12-O-tetradecano-
yl phorbol 13-acetate (TPA) can stimulate the trans-di¡eren-
tiation of avian neural crest-derived Schwann cell precursors
into melanocytes. The TPA-induced di¡erentiation process is
blocked with antisense RNA targeted against FGF-2 mRNA
[35]. In this same study, an antagonist of FGFR binding and
activity (inositol-hexakisphosphate: InsP6), or FGF-2-neu-
tralising antibodies, had no e¡ect on TPA-induced di¡erentia-
tion, thus indicating the crucial involvement of intracellular
FGF-2 proteins in melanogenesis.
The antisense methodology also allowed the elucidation of
the intracrine e¡ect of FGF-2 on transformation and tumori-
genesis of the SK-Hep1 hepatoma cell line, which naturally
produces all the FGF-2 isoforms. Inhibition of FGF-2 syn-
thesis in these cells led to a loss of anchorage independence in
soft agar, and this e¡ect was not reversed by the addition of
exogenous FGF-2 [36].
In the development of the rat heart, the question of a pu-
tative distinct role of the high and low molecular weight iso-
forms of FGF-2 has also been addressed. Neonatal rat cardiac
myocytes were transfected with cDNA of both isoforms [37].
Both the 18 kDa and HMW FGF-2 a¡ected proliferation via
a paracrine mechanism, but overexpression of the HMW iso-
forms only led to a signi¢cant increase in cell binucleation,
which was not a¡ected by neutralising antibodies against
FGF-2. Here again, the preferential synthesis of the nuclear
isoforms of FGF-2 versus the 18 kDa protein correlates with
di¡erential e¡ects on cell phenotype.
A selective overexpression of HMW FGF-2 has also been
frequently characterised in human tumour cells surviving ir-
radiation treatment. As such, the distinct behaviour of the
FGF-2 species has been studied in a model of cell radioresist-
ance acquisition. Transfecting HeLa cells with FGF-2-coding
vectors, Cohen-Jonathan et al. [38] observed that cells over-
expressing the 24 kDa FGF-2 become radioprotected com-
pared to the wild type or 18 kDa FGF-2-transfected cells.
This radioresistance was associated with an increased G2 de-
lay after irradiation and the hyperphosphorylation of p34cdc2
kinase.
Finally, it has also been shown that while the glioma cells
do not respond to extracellular FGF-2 stimulus, their prolif-
eration rate strongly increases when transfected with FGF-2-
expressing vectors. This e¡ect is una¡ected by the InsP6 an-
tagonist that disrupts FGF-2 binding to plasma membrane
receptors, and is correlated with nuclear accumulation of
FGF-2 [39]. Moreover, in the PC12 cell line, overexpression
of HMW FGF-2 stabilises the endocrine phenotype, while the
18 kDa protein led these cells to di¡erentiate towards the
neuronal phenotype [40].
6. Intracellular FGF-2 can direct gene regulation
As increasing evidence for the di¡erential activity of HMW
FGF-2 has accumulated, an investigation into the intracellular
targets of these proteins has been addressed. In 1992, Naka-
nishi et al. [41] ¢rst demonstrated a direct modulation of gene
activity by FGF-2 in a cell-free system. Using nuclear extracts
of Ehrlich ascites tumour cells, they analysed the e¡ect of the
recombinant 18 kDa FGF-2 isoform on the expression of the
mouse phosphoglycerate kinase 1 and 2 (Pgk-1 and Pgk-2)
isozyme genes. These proteins are involved in the transcrip-
tional switch occurring during spermatogenesis and evolve
from the somatic-type Pgk-1 to the sperm-speci¢c Pgk-2.
The authors showed that FGF-2 modulates transcription of
Pgk-1 and Pgk-2 genes in a dose-dependent and promoter-
speci¢c manner, stimulating Pgk-2 while inhibiting Pgk-1
transcription.
More recently, Delrieu and colleagues investigated whether
or not nuclear FGF-2 could be involved in the regulation of
another multifunctional cytokine expression: IL-6. Part of
this work, using cotransfection systems in NIH-3T3 ¢bro-
blasts [42], showed that while exogenously added 18 kDa
FGF-2 results in a down-regulation of IL-6 expression, the
nuclear 24 kDa isoform leads to accumulation of the IL-6
mRNA. This was shown to occur via activation of the IL-6
promoter. However, the overexpression of 24 kDa FGF-2 in
HeLa human cells led to an inhibition of the IL-6 promoter
activity, hence revealing a cell-speci¢c e¡ect of this nuclear
isoform on IL-6 transcriptional regulation [43]. When inves-
tigating further this down-modulation, it appeared that nei-
ther the AP-1, NF-UB nor NF-IL-6 elements on the IL-6
promoter were involved. On the contrary, the deletion of a
short region, containing a retinoblastoma control element
(RCE) consensus sequence, abolished the e¡ect of the 24
kDa protein, indicating that RCE could be a direct or indirect
nucleic target for the nuclear activities of the HMW FGF-2
molecules.
7. Conclusion
Taken together, these ¢ndings emphasise the complexity of
the mechanisms accounting for the biological activities of
FGF-2. As for another member of the FGF family, FGF-1
[44], intracellular proteins of FGF-2 are responsible for some
of its important biological activities, e.g. growth in low serum
conditions and survival phenotype acquisition. Nevertheless,
apart from the internalisation process of extracellular growth
factor molecules, de novo synthesis of the nuclear HMW iso-
forms accounts for the nuclear localisation of FGF-2. As a
result, HMW FGF-2 appears to play a role in the regulation
of gene expression in the mediation of these speci¢c e¡ects. It
is very likely that the di¡erential signalling pathway between
the 18 kDa and HMW FGF-2 depends more on their distinct
subcellular location than on their respective biochemical fea-
tures, e.g. amino-terminal extensions. Indeed, both puri¢ed
species compete for the same high a⁄nity membrane receptors
when administered to endothelial cells, and hence are similarly
capable of inducing plasminogen activator production as well
as proliferation and migration [45]. In addition, both 18 kDa
FGF-2 and HMW FGF-2 are capable of binding non-specif-
ically and with high a⁄nity to nuclear chromatin, suggesting
that sequences within the 18 kDa protein, but not the amino-
terminal extension, are necessary for this binding. This hy-
pothesis has been recently con¢rmed by Arese et al. [46] using
arti¢cially nucleus-targeted 18 kDa FGF-2. When overex-
pressing these constructs in NIH-3T3 cells, the authors
showed that the ‘core’ 18 kDa molecule of FGF-2 is the bio-
logical messenger for the mitogenic activity under serum star-
vation conditions. In addition, the LMW and HMW FGF-2
FEBS 23334 10-2-00
I. Delrieu/FEBS Letters 468 (2000) 6^10 9
isoforms have been shown to be involved in di¡erent molec-
ular protein complexes in the cytosol and nucleus [47].
Hence, FGF-2 is capable of controlling several distinct ac-
tivities via di¡erent signal transduction pathways, depending
on its speci¢c cellular localisation which itself relies on tightly
regulated alternative translation mechanisms. Intracellular
FGF-2 molecules can be targeted to the nucleus via NLS-
independent (internalised 18 kDa), or NLS-dependent
(HMW isoforms or arti¢cial NLS 18 kDa recombinant pro-
teins) pathways. Depending on the pathway involved, they
might be addressed to distinct subcellular/subnuclear com-
partments where they may associate with distinct e¡ectors,
hence resulting in distinct biological responses.
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